Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
Primary Objective
The purpose of this study is to learn more about the effects of an investigational drug called semaglutide as a safe and effective means of improving cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes.
Description
Randomized clinical trial to assess the effects of 8 months of once-weekly subcutaneous semaglutide vs. once-weekly placebo injection.
Details
Locations
Anschutz Health and Wellness
Barbara Davis Center
Brain Imaging Center (BIC)
CTRC Inpatient
CU-RIC
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Kristen Nadeau
Study ID
Protocol Number: 22-0794
More information available at ClinicalTrials.gov: NCT05819138
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers